Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromfenac for CME prevention after cataract surgery
NCT06785090Phase 4Completed
- Start
- May 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bromfenac sodium in cystoid macular edema (CME). Primary endpoint: Change in Macular Thickness From Baseline to 6 Weeks Postoperatively. Started May 2023; status: completed.
02
Drugs
bromfenac sodium
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on NCT06785090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785090.